Biosimilars

COVID-19

Cataract Surgery

Cataract

Cataract Therapeutics

NeuroOp Guru

Clinical Diagnosis

Cornea

Dry Eye Awareness

Dry Eye

Gene Therapy

Geographic Atrophy

IOL Advances

Imaging

Glaucoma Awareness

Glaucoma Insights

Therapeutic Glaucoma

Interventional Glaucoma

Ocular Allergy

Ocular Surface Disease

Optic Relief

Optometry

Pediatrics

Pharmacy

Indispensable

Practice Management

Presbyopia

Ptosis

Refractive Surgery

Refractive

Retina

Surgery

Technology

Therapeutics

Understanding Antibiotic Resistance

Workplace

News

All News

Contributors

Money Matters

Media

All Videos

Expert Interviews

Medical World News

Podcasts

Case Based Roundtable Series

Case of the Quarter

EyeView

Grand Rounds

Insights

Rapid Readout

Viewpoints

What’s Your WhEYE?

Conferences

Conference Coverage

Conference Listing

Events

Publications

Digital Edition

Europe Ophthalmology Times

Modern Retina

Supplements and Featured Publications

Partners

Subscribe

Resources

Job Board

Articles

The company stated that the FDA noted at least one additional adequate and well controlled study to demonstrate a positive effect on the treatment of ocular symptoms of dry eye should be conducted.

FDA issues Complete Response Letter to Aldeyra Therapeutics for resubmitted New Drug Application of reproxalap

Methylphenidate is a central nervous system stimulant that is used to treat ADHD, a very common diagnosis in children in the US.

Methylphenidate may impact corneal cells in children with ADHD

He is editor of The Neuro-Connection. He is professor of ophthalmology, neurology, and neurosurgery, The H. Stanley Thompson Neuro-ophthalmology Clinic, Department of Ophthalmology at the University of Iowa Hospitals and Clinics, Iowa City.

Videos

Sheryl brings a wealth of editorial experience to MJH Life Sciences’ Eye Care Network, having engaged with the readers and the greater ophthalmic community of 

for more than 20 years. As Group Editorial Director, Sheryl’s purview extends across the print and digital network of 

Ophthalmology Times, Ophthalmology Times Europe, Modern Retina 

 Prior to ophthalmology, Sheryl previously covered the fields of audiology and confectionery science/technology/manufacturing.

Sheryl is also passionate about the mission, vision and values of Ophthalmic World Leaders (OWL) and recently completed her term on its Board of Directors. She continues to volunteer as Editor-in-Chief of the organization’s 

Magazine. In 2013, she was honored with the group’s inaugural Rising Star Award.

In addition, she has served as a judge for 

 Health Care Heroes Awards program as well as the Jesse H. Neal National Business Journalism Awards.

Andrew G. Lee, MD, and Drew Carey, MD, return for this episode of 'NeuroOp Guru' to discuss how sixth nerve palsy with chemosis warrants suspicion for a cavernous carotid fistula, emphasizing careful examination for dilated conjunctival vessels and the need for imaging for accurate diagnosis and timely intervention.

NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula

In celebration of Ophthalmology Times 50th anniversary, we asked leading experts in the field what they see as the biggest innovation in ophthalmology in the last 5 decades.

Part 3: Biggest innovations in ophthalmology in 50 years

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic community.

About

Advertise

Privacy

Editorial Info

Editorial Board

Terms and Conditions

Contact Us

Do Not Sell My Personal Information

Ophthalmology Times - Ophthalmology news, articles, and events

Facebook

Instagram

LinkedIn

Spotlight

Clinical

Glaucoma

View

Dr. Kornmehl: Thank you all for participating in this discussion about conductive keratoplasty (CK). Ed, what is the mechanism of CK

Conductive keratoplasty becomes new player in refractive surgery market